FDA Approves New Treatment for HER2-positive Breast Cancer
The U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called fam-trastuzumab deruxtecan-nxki (Enhertu) for treating...
Category: Policy
The U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called fam-trastuzumab deruxtecan-nxki (Enhertu) for treating...
In the final days of 2019, the U.S. Food and Drug Administration (FDA) expanded the use of a previously...
In 2019, research continued to drive progress across the spectrum of cancer care in the form of new and...
In November and the first half of December, the U.S. Food and Drug Administration (FDA) announced three approvals for...
As 2019 draws to a close, the American Association for Cancer Research (AACR) is grateful for our growing ranks...
Earlier this month, the U.S. Food and Drug Administration (FDA) announced that the Office of Hematology and Oncology Products...
On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula)...
Breast cancer can be a scary diagnosis. Even though mortality rates have declined in recent years in the United...
The use of immunotherapy in the treatment of cancer has dramatically increased in the five years since the U.S....
In the effort to include more diverse patient populations in clinical trials, good intentions can easily go awry. Panelists...